학술논문
Genome-wide association study identifies novel loci for type 2 diabetes-attributed end-stage kidney disease in African Americans.
Document Type
article
Author
Guan, Meijian; Keaton, Jacob M; Dimitrov, Latchezar; Hicks, Pamela J; Xu, Jianzhao; Palmer, Nicholette D; Ma, Lijun; Das, Swapan K; Chen, Yii-Der I; Coresh, Josef; Fornage, Myriam; Franceschini, Nora; Kramer, Holly; Langefeld, Carl D; Mychaleckyj, Josyf C; Parekh, Rulan S; Post, Wendy S; Rasmussen-Torvik, Laura J; Rich, Stephen S; Rotter, Jerome I; Sedor, John R; Thornley-Brown, Denyse; Tin, Adrienne; Wilson, James G; Freedman, Barry I; Bowden, Donald W; Ng, Maggie CY; FIND Consortium
Source
Human genomics. 13(1)
Subject
Language
Abstract
BackgroundEnd-stage kidney disease (ESKD) is a significant public health concern disproportionately affecting African Americans (AAs). Type 2 diabetes (T2D) is the leading cause of ESKD in the USA, and efforts to uncover genetic susceptibility to diabetic kidney disease (DKD) have had limited success. A prior genome-wide association study (GWAS) in AAs with T2D-ESKD was expanded with additional AA cases and controls and genotypes imputed to the higher density 1000 Genomes reference panel. The discovery analysis included 3432 T2D-ESKD cases and 6977 non-diabetic non-nephropathy controls (N = 10,409), followed by a discrimination analysis in 2756 T2D non-nephropathy controls to exclude T2D-associated variants.ResultsSix independent variants located in or near RND3/RBM43, SLITRK3, ENPP7, GNG7, and APOL1 achieved genome-wide significant association (P